<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunningham, Muriel</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Mauri, Laura</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">DAPT Study: Benefits Seen with Prolonged DAPT after DES Treatment</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">The Dual Antiplatelet Therapy [DAPT] trial recruited patients from 5 studies conducted at 452 sites in 11 countries. The objective was to assess the efficacy and safety of dual antiplatelet therapy (DAPT) between 12 and 30 months in patients treated with coronary stents. This article discusses the primary results of the DAPT trial in the cohort treated with drug-eluting stents.</style></abstract><number><style face="normal" font="default" size="100%">52</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>